Univercells is a medical engineering company having developed technologies aiming at reducing the cost of vaccines and biologics by significant factors. Amongst others, it has attracted the attention of the Bill & Melinda Gates Foundation and other prominent international investors and been granted important subsidies. The Series B was led by American and Korean professional PE Funds and TCD Capital has managed the Belgian anchorage by co-investing with prominent Belgian investors. TCD Capital Fund II has invested in the Serie C, as led by Adjuvant Capital, an American PE Fund. The company has announced aiming an IPO on the NASDAQ by 2022.